ClinicalTrials.gg
CompletedNCT00798967STEPSUpdated Jun 3, 2021Results posted

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

A Phase 3 interventional study of teduglutide and placebo in Short Bowel Syndrome, sponsored by Shire. Completed at 35 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
2nd of 20
86 · median 20
Started
2008
the only one that year
Phase 3
16 of 20
none open now
Registered
3rd of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 16 in phase 3, and was the 3rd registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • SBS
  • short bowel syndrome
  • TPN
  • parenteral nutrition
  • PN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated prior to any study-related procedures are performed
  • Men and women 18 years of age or older at the time of informed consent signing
  • Intestinal failure resulting in Short Bowel Syndrome
  • At least 12 months of continuous PN dependency
  • 12 weeks of clinical remission of Crohn's disease (CD) prior to dosing
  • PN required at least 3 times weekly
  • A stable PN volume for four weeks prior to dosing

Exclusion criteria

Exclusion Criteria:

  • History of cancer or lymphoproliferative disease with fewer than 5 years documented disease-free state
  • Participation in clinical study within 30 days for drug or 90 days for antibody
  • Use of native GLP-2 or human growth hormone (HGH) within 6 months of screening
  • Use of iv glutamine within 30 days prior to screening
  • Use of teduglutide
  • CD patients who have been treated with biological therapy within 6 months of screening
  • IBD patients who require chronic systemic therapy
  • More than 4 SBS- or PN-related hospitalizations within 12 months of screening
  • Unplanned hospitalization within one month of screening
  • Pregnant or lactating women
  • Body weight > 88kg
  • (BMI) \< 15 kg/m2
  • Severe hepatic impairment or disturbed renal function
  • Female subjects who are not surgically sterile or or who are not using medically acceptable methods of during and for 30 days after the treatment period
  • Not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements
  • Any condition or circumstance that is the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with the analysis of the study results
  • Significant active, uncontrolled, untreated systemic diseases
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Teduglutide

    0.05 mg/kg/day sc dose of teduglutide

    Drug: teduglutide

  • Placebo comparator
    Placebo

    Matching subcutaneous dose of placebo to teduglutide

    Drug: placebo

Interventions

  • 0.05 mg/kg/day sc injection for 24 weeks

    Also known as: GATTEX, ALX-0600

  • Drugplacebo

    Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks

06

What researchers measure

Primary outcomes

  1. Responder

    Comparison of subjects treated with teduglutide to placebo who achieve a 20 to 100% reduction from baseline in weekly parenteral nutrition/intravenous fluid (PN/I.V.) volume at weeks 20 and 24.

    Time frame: Weeks 20 and 24

Secondary outcomes

  1. Absolute Change in PN/I.V. Volume From Baseline to Last Time Point

    Absolute change in the volume of PN/I.V. from baseline (Week 0) to the visit when the last data point was collected (week 4 through week 24, or earlier if the subject discontinued early).

    Time frame: Week 0 to last visit when data was collected.

07

Results

Posted Feb 1, 2012

Participant flow

First Patient Screened - November 25, 2008; Last Patient Screened - July 13, 2010; First Patient Randomized - March 3, 2009; Last Patient Randomized - July 22, 2010; Locations - hospitals and transplant centers; Subjects must be on parenteral nutrition (PN) and/or intravenous (I.V.) fluids.

Participant flow — Overall Study
MilestoneTeduglutidePlacebo
Started4343
Discontinued during dosing period44
Completed3939
Not completed44
Withdrew: Adverse event23
Withdrew: Withdrawal by subject01
Withdrew: Physician decision10
Withdrew: Randomized in error by site10

Outcome measures

PrimaryResponder

Comparison of subjects treated with teduglutide to placebo who achieve a 20 to 100% reduction from baseline in weekly parenteral nutrition/intravenous fluid (PN/I.V.) volume at weeks 20 and 24.

Time frame:
Weeks 20 and 24
Reported as:
Number · subjects
Responder
subjectsTeduglutidePlacebo
Responder2713
Statistical analysis
  • Teduglutide vs Placebo · Cochran-Mantel-Haenszel · p = 0.002 (Cochran-Mantel-Haenszel (CMH) test adjusted for the randomization stratification variable (\<= 6 or \> 6 L/week of PN at baseline))
SecondaryAbsolute Change in PN/I.V. Volume From Baseline to Last Time Point

Absolute change in the volume of PN/I.V. from baseline (Week 0) to the visit when the last data point was collected (week 4 through week 24, or earlier if the subject discontinued early).

Time frame:
Week 0 to last visit when data was collected.
Reported as:
Mean · Liters/Week
Absolute Change in PN/I.V. Volume From Baseline to Last Time Point
Liters/WeekTeduglutidePlacebo
Absolute Change in PN/I.V. Volume From Baseline to Last Time Point-4.28 ± 3.81-2.38 ± 2.79
Statistical analysis
  • Teduglutide vs Placebo · ANCOVA · p = < 0.001

Adverse events

Collected over Adverse event data were collected for each subject from the time informed consent was signed to end of study. For this reporting of adverse event, the most commonly reported treatment emergent adverse events (>=3 subjects at SOC level) are listed.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teduglutide—15/42 (35.7%)35/42 (83.3%)
Placebo—12/43 (27.9%)34/43 (79.1%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventTeduglutidePlacebo
Catheter-related infectionInfections and infestations5/421/43
BacteremiaInfections and infestations0/423/43
Central line infectionInfections and infestations2/423/43
Urinary tract infectionInfections and infestations2/421/43
Device dislocationInjury, poisoning and procedural complications0/422/43
Adenovirus infectionInfections and infestations1/420/43
Catheter sepsisInfections and infestations1/420/43
Catheter-related complicationGeneral disorders1/420/43
Cholecystitis acuteHepatobiliary disorders1/420/43
DehydrationMetabolism and nutrition disorders1/420/43
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTeduglutidePlacebo
Abdominal painGastrointestinal disorders13/4210/43
NauseaGastrointestinal disorders12/428/43
Gastrointestinal stoma complicationInjury, poisoning and procedural complications10/423/43
Abdominal distensionGastrointestinal disorders9/421/43
Central line systemic infectionsInfections and infestations7/427/43
Edema peripheralGeneral disorders7/422/43
Urinary tract infectionInfections and infestations6/424/43
FlatulenceGastrointestinal disorders5/423/43
VomitingGastrointestinal disorders5/424/43
DiarrheaGastrointestinal disorders3/425/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)TeduglutidePlaceboTotal
Mean50.9 ± 12.649.7 ± 15.650.3 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)TeduglutidePlaceboTotal
Female222446
Male211940
08

Study locations

35 sites
  • Scripps Clinic & Research Foundation
    La Jolla, California 92037, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennslyvania
    Philadelphia, Pennsylvania 19104, United States
  • University Of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Critical Care Research, Royal Alexandra Hospital
    Edmonton, Alberta T5H 3V9, Canada
  • Hamilton Health Sciences Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • Polyclinic Family and Specialty Medicine Facility
    North York, Ontario M3H 5S4, Canada
  • University Health Network - Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Rigshospitalet - Abdominalcentret, Hepatologisk Kilinik A
    København, 2100, Denmark
  • Hôpital Beaujon
    Clichy, 92110, France
  • Hôpital Croix Rousse Unité de Nutrition Clinique Intensive
    Lyon, France
  • Hôpital de l'Archet Pôle Digestif
    Nice Cedex 3, 06100, France
  • Med. Klinik m.S. Hepatologie und Gastroenterologie
    Berlin, BE 13353, Germany
  • Universitaetsklinikum Tuebingen
    Tuebingen, BW 72076, Germany
  • Israelitisches Krankenhaus
    Hamburg, HH 22297, Germany
  • Azienda Ospedaliera Universitaria S. Giovanni Battista - Le Molinette
    Torino, TO 10126, Italy
  • Policlinico Sant'Orsola - Malpighi centro insufficienza intestinale
    Bologna, 40138, Italy
  • Azienda Universitaria Policlinico Federico II
    Napoli, 80131, Italy
  • Universitair Medisch Centrum St. Radboud
    Nijmegen, 6525 GA, Netherlands
  • Wojewodzki Szpital Specjalistyczny im. M. Pirogowa, Pracownia Leczenia Zywieniowego
    Lodz, 90-531, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Chirurgii Ogolnej i Transplantacyjnej
    Lublin, 20-954, Poland
  • Wojewodzki Szpital Specjalistyczny,
    Olsztyn, 10-561, Poland
  • Samodzielny Publiczny Szpital Kliniczny im. prof W. Orlowskiego CMKP, Oddzial Kliniczny Zywienia i Chirurgii
    Warsaw, 00-416, Poland
  • Hospital Universitario de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • St. Mark's Hospital Northwick Park
    Harrow, Gt Lon HA1 3UJ, United Kingdom
  • University College Hospital
    London, Gt Lon NW1 2BU, United Kingdom
  • Green Area, Main Hospital Salford Royal Hospitals NHS Foundation Trust
    Manchester, Gt Man M6 8HD, United Kingdom
09

References and documents

Publications

  • Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005 Sep;54(9):1224-31. doi: 10.1136/gut.2004.061440. PubMed 16099790 ↗
  • Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C. Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study. Clin Nutr. 2020 Aug;39(8):2479-2486. doi: 10.1016/j.clnu.2019.11.001. Epub 2019 Nov 9. PubMed 31784300 ↗
  • Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology. 2018 Mar;154(4):874-885. doi: 10.1053/j.gastro.2017.11.023. Epub 2017 Nov 22. PubMed 29174926 ↗
  • Fujioka K, Jeejeebhoy K, Pape UF, Li B, Youssef NN, Schneider SM. Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. JPEN J Parenter Enteral Nutr. 2017 Nov;41(8):1419-1422. doi: 10.1177/0148607116663481. Epub 2016 Aug 9. PubMed 27507402 ↗
  • Vipperla K, O'Keefe SJ. Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects. Expert Rev Gastroenterol Hepatol. 2013 Nov;7(8):683-7. doi: 10.1586/17474124.2013.842894. Epub 2013 Oct 17. PubMed 24134154 ↗
  • Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, Messing B, Loth S, Youssef NN, Heinze H, Berghofer P. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. Clin Nutr. 2013 Oct;32(5):713-21. doi: 10.1016/j.clnu.2013.03.016. Epub 2013 Mar 28. PubMed 23587733 ↗
  • Berghofer P, Fragkos KC, Baxter JP, Forbes A, Joly F, Heinze H, Loth S, Pertkiewicz M, Messing B, Jeppesen PB. Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL) scale. Clin Nutr. 2013 Oct;32(5):789-96. doi: 10.1016/j.clnu.2012.12.001. Epub 2012 Dec 12. PubMed 23274148 ↗
  • Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, Forbes A, Heinze H, Joelsson B. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012 Dec;143(6):1473-1481.e3. doi: 10.1053/j.gastro.2012.09.007. Epub 2012 Sep 11. PubMed 22982184 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Jan 2011, 26 months.

Results were first posted in Feb 2012, 1 year after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 26 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2008
First posted
Nov 27, 2008
StartActual
Nov 25, 2008
Primary completionActual
Jan 25, 2011
CompletionActual
Jan 25, 2011
Results first posted
Feb 1, 2012
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00798967
Lead sponsor
Shire
Collaborators
Nycomed
Responsible party
Sponsor
First posted
Nov 27, 2008
Start date
Nov 25, 2008
Primary completion
Jan 25, 2011
Completion
Jan 25, 2011
Results posted
Feb 1, 2012
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion